Home » Topics » BioWorld Science

BioWorld Science
RSS

Hoechst Marion Roussel claims compound for neurodegenerative disorders

Sep. 13, 1996

Side effects of botulinum toxin A in the treatment of craniocervical dystonias

Sep. 13, 1996

Rhodanines for multiple sclerosis

Sep. 13, 1996

New treatment strategy for Parkinson's disease introduced

Sep. 13, 1996

New formulation of selegiline

Sep. 13, 1996

Dopaminergic agents claimed by Sandoz

Sep. 13, 1996

ImmunoTherapeutics name change

Sep. 13, 1996

Stryker acquires Osteo

Sep. 13, 1996

Proposed acquisition agreement between Genzyme and Neozyme II

Sep. 13, 1996

Hybridon enters research collaborations for antisense therapies

Sep. 13, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.